October 29, 2015 9:54am
The United States Patent and Trademark Office has granted a key patent covering the use of its proprietary adult mesenchymal precursor cells (MPCs) for the formation and repair of blood vessels in ischemic tissues.
US Patent No. 9,169,466 entitled Perivascular Mesenchymal Precursor Cell Induced Blood Vessel
The Bottom Line: The granted claims cover the use of the company's allogeneic or off-the-shelf MPCs obtained from any source, for use in conditions including ischemic heart disease, stroke and peripheral arterial disease. Formation provides commercial rights in the United States through to January 8, 2025 in line with adjustments. Further patent term extension may occur along with regulatory exclusivity extensions.
This newly granted patent extends and broadens Mesoblast's intellectual property position in the United States with respect to the treatment of cardiac and vascular diseases beyond the previously granted patents US7514074, US7892829, US8158120, US8158121, US8852570, US8852571, US8852572, US8852573, US8852574 and US8852575 which cover allogeneic culture-expanded Mesenchymal Stem Cell product candidates for cardiovascular diseases.
